title: The skeletal site-differential changes in bone mineral density following bone marrow transplantation: 3-year prospective study.
abstract: Loss of bone mass is usually detected after bone marrow transplantation (BMT) during the early post-transplant period. However, little is known about the long-term effects of BMT on bone metabolism. We have prospectively investigated 11 patients undergoing BMT. Bone mineral density (BMD) was measured before BMT, and 1, 2, and 3 yr after BMT. Serum markers of bone turnover were serially measured before BMT and 1, 2, 3, 4, and 12 weeks, 6 months, and 1 yr after BMT. The mean change in the lumbar spine (L2-4) BMD, calculated as the percent change from the baseline to the level at 1, 2, and 3 yr was -4.7% (NS), -1.1% (NS), and +6.4% (p<0.05), respectively. The mean change in the total proximal femur BMD from the baseline to the level at 1, 2, and 3 yr was -8.5% (p<0.01), -8.7% (p<0.05) and -5.6% (p<0.05), respectively. In summary, there was little decline in lumbar BMD at 1 yr following BMT and gradual recovery until 3 yr. In contrast, femoral BMD decreased much more than the lumbar area at 1 yr and did not recover until 3 yr. The mechanism of skeletal site-selective differences in the changes of BMD needs to be elucidated.
authors.affiliation: Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. drlwy@samsung.co.kr
authors.forename: Won Young
authors.initials: WY
authors.lastname: Lee
authors.forename: Moo Il
authors.initials: MI
authors.lastname: Kang
authors.forename: Ki Hyun
authors.initials: KH
authors.lastname: Baek
authors.forename: Eun Sook
authors.initials: ES
authors.lastname: Oh
authors.forename: Ki Won
authors.initials: KW
authors.lastname: Oh
authors.forename: Kwang Woo
authors.initials: KW
authors.lastname: Lee
authors.forename: Sun Woo
authors.initials: SW
authors.lastname: Kim
authors.forename: Choon Choo
authors.initials: CC
authors.lastname: Kim
mesh_terms: D000328:Adult; D000367:Age Factors; D000741:Anemia, Aplastic / Q000628:therapy; D015519:Bone Density; D016026:Bone Marrow Transplantation; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism* / Q000528:radiation effects; D003094:Collagen / Q000097:blood; D024042:Collagen Type I; D003520:Cyclophosphamide / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007938:Leukemia / Q000628:therapy; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy; D010455:Peptides / Q000097:blood; D011446:Prospective Studies; D013997:Time Factors
chemical_list: D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D004958:Estradiol; D003520:Cyclophosphamide; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003094:Collagen